Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

REPLIMUNE GROUP, INC.

(REPL)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
28.29 USD   -2.75%
01/23Certain Pre-funded Warrants of Replimune Group, Inc. are subject to a Lock-Up Agreement Ending on 23-JAN-2023.
CI
01/23Certain Warrants of Replimune Group, Inc. are subject to a Lock-Up Agreement Ending on 23-JAN-2023.
CI
01/23Certain Restricted Stock Units of Replimune Group, Inc. are subject to a Lock-Up Agreement Ending on 23-JAN-2023.
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Replimune, Roche to Develop RP3 in Colorectal Cancer, Hepatocellular Carcinoma

12/07/2022 | 07:29am EST

By Colin Kellaher


Replimune Group Inc. on Tuesday said it inked a deal to work with Swiss pharmaceutical company Roche Holding AG to advance Replimune RP2/3 program in colorectal cancer and hepatocellular carcinoma.

Replimune said Roche would share costs to develop RP3 in combination with Roche's cancer drugs Tecentriq and Avastin in third-line colorectal cancer and in second-line hepatocellular carcinoma.

Replimune, a Woburn, Mass., clinical-stage biotechnology company, said Roche would also supply Tecentriq and Avastin for combination studies of RP3 in first-line hepatocellular carcinoma and RP2 in third-line colorectal cancer.

Replimune, which has similar collaborations in place for its lead candidate RP1 with Regeneron Pharmaceuticals Inc. and Bristol Myers Squibb Co., said it is on track to initiate its Phase 2 development program with RP2/3 in the first half of 2023.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

12-07-22 0729ET

Stocks mentioned in the article
ChangeLast1st jan.
REGENERON PHARMACEUTICALS, INC. 4.25% 783.13 Delayed Quote.8.54%
REPLIMUNE GROUP, INC. -2.75% 28.29 Delayed Quote.4.01%
ROCHE HOLDING AG 3.10% 282.35 Delayed Quote.-2.81%
All news about REPLIMUNE GROUP, INC.
01/23Certain Pre-funded Warrants of Replimune Group, Inc. are subject to a Lock-Up Agreemen..
CI
01/23Certain Warrants of Replimune Group, Inc. are subject to a Lock-Up Agreement Ending on ..
CI
01/23Certain Restricted Stock Units of Replimune Group, Inc. are subject to a Lock-Up Agree..
CI
01/23Certain Stock Options of Replimune Group, Inc. are subject to a Lock-Up Agreement Endin..
CI
01/23Certain Common Stock of Replimune Group, Inc. are subject to a Lock-Up Agreement Ending..
CI
01/09Transcript : Replimune Group, Inc. Presents at 41st Annual J.P. Morgan Health..
CI
01/05EF Hutton Starts Replimune Group at Buy With $60 Price Target
MT
01/05Replimune : Corporate Presentation January 2023
PU
01/04Replimune Group, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form ..
AQ
01/04Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
More news
Analyst Recommendations on REPLIMUNE GROUP, INC.
More recommendations
Financials (USD)
Sales 2023 - - -
Net income 2023 -172 M - -
Net cash 2023 293 M - -
P/E ratio 2023 -9,39x
Yield 2023 -
Capitalization 1 600 M 1 600 M -
EV / Sales 2023 -
Capi. / Sales 2024 0,23x
Nbr of Employees 206
Free-Float 82,1%
Chart REPLIMUNE GROUP, INC.
Duration : Period :
Replimune Group, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REPLIMUNE GROUP, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 28,29 $
Average target price 51,50 $
Spread / Average Target 82,0%
EPS Revisions
Managers and Directors
Philip Astley-Sparke Chief Executive Officer & Director
Robert Coffin President & Director
Jean M. Franchi Chief Financial Officer, Secretary & Treasurer
Dieter Weinand Chairman
Colin A. Love Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
REPLIMUNE GROUP, INC.4.01%1 600
MODERNA, INC.-3.55%66 559
LONZA GROUP AG21.92%44 368
IQVIA HOLDINGS INC.15.76%44 054
ALNYLAM PHARMACEUTICALS, INC.-1.80%28 711
SEAGEN INC.7.38%25 622